Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits

Journal of Thoracic and Cardiovascular Surgery

Volumn 101, Issue 4, 1991, Pages 654-660

  Videm, V ^a   Mollnes, T E ^a   Garred, P ^a   Svennevig, J L ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ARTICLE; COMPLEMENT ACTIVATION; ERYTHROCYTE; EXTRACORPOREAL CIRCULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE;

EID: 0025911727     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5223(19)36696-6     Document Type: Article

References (31)

1. Hakim RM Breillatt J Lazarus JM Port FK Complement activation and hypersensitivity reactions to dialysis membranes N Engl J Med 311 1984 878 882
2. Mollnes TE Lachmann P Regulation of complement Scand J Immunol 27 1988 127 142
3. Chenoweth DE Cooper SW Hugli TE Steward RW Blackstone EH Kirklin JW Complement activation during cardiopulmonary bypass. Evidence for generation of C3a and C5a anaphylatoxins N Engl J Med 304 1981 497 502
4. Best N Sinosich MJ Teisner B Grudzinskas JG Fisher M Complement activation during cardiopulmonary bypass by heparin-protamine interaction Br J Anaesth 56 1984 339 343
5. Mollnes TE Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex Complement 2 1985 156 164
6. Fosse E Mollnes TE Ingvaldsen B Complement activation during major operations with or without cardiopulmonary bypass J T horac C ardiovasc S urg 93 1987 860 866
7. Moore FD Warner KG Assousa S Valeri CR Khuri SF The effects of complement activation during cardiopulmonary bypass Ann Surg 208 1988 95 103
8. Balzo UHD Levi R Polley MJ Cardiac dysfunction caused by human C3a anaphylatoxin Proc Natl Acad Sci USA 82 1985 886 890
9. Hammerschmidt DE Harnes PE Wayland JH Craddock PR Jacob HS Complement induced granulocyte aggregation in vivo Am J Pathol 102 1981 146 150
10. Kirklin JK Westaby S Blackstone EH Kirklin JW Chenoweth DE Pacifico AD Complement and the damaging effects of cardiopulmonary bypass J T horac C ardiovasc S urg 86 1983 845 857
11. Salama A Hugo F Heinrich D Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass N Engl J Med 318 1988 408 414
12. van Oeveren W Kazatchkine MD Descamps-Latscha B Deleterious effects of cardiopulmonary bypass J T horac C ardiovasc S urg 89 1985 888 899
13. Videm V Fosse E Mollnes TE Garred P Complement activation by extracorporeal circulation: effects of precoating a membrane oxygenator circuit with human whole blood Scand J Thorac Cardiovasc Surg 22 1988 251 256
14. Kazatchkine MD Fearon DT Silbert JE Austen KF Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b J Exp Med 150 1979 1202 1215
15. Larm O Larsson R Olsson P A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue Biomater Med Dev Artif Org 11 1983 161 173
16. Garred P Mollnes TE Lea T Quantification in ELISA of a C3 neoepitope expressed on activated human complement factor C3 Scand J Immunol 27 1988 329 335
17. Mollnes TE Antigenic changes of complement components: relevance for the analysis of complement activation Complement Inflamm 6 3 1989 134 141
18. Mollnes TE Lea T Frøland SS Harboe M Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against neo-antigen of the complex Scand J Immunol 22 1985 197 202
19. Conover WJ Practical nonparametric statistics 2nd ed 1980 John Wiley New York 229 237 299–308
20. Tamiya T Yamasaki M Maeo Y Yamashiro T Ogoshi S Fujimoto S Complement activation in cardiopulmonary bypass, with special reference to anaphylatoxin production in membrane and bubble oxygenators Ann Thorac Surg 46 1988 47 57
21. Weiler JM Yurt RW Fearon DT Austen KF Modulation of the formation of the amplification convertase of complement, C3b,Bb, by native and commercial heparin J Exp Med 147 1978 409 421
22. Kazatchkine MD Fearon DT Metcalfe DD Rosenberg RD Austen KF Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase J Clin Invest 67 1981 223 228
23. Wegmüller E Kazatchkine MD Nydegger UE Complement activation during extracorporeal blood bypass Plasma Ther Transfus Technol 4 1983 361 371
24. Videm V Fosse E Mollnes TE Ellingsen Ø Pedersen T Karlsen H Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro J T horac C ardiovasc S urg 97 1989 764 770
25. Jenne D Stanley KK Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion EMBO J 4 1985 3153 3157
26. Yatohgo T Izumi M Kashiwagi H Hayashi M Novel purification of vitronectin from human plasma by heparin affinity chromatography Cell Struct Funct 13 4 1988 281 292
27. Bhakdi S Fassbender W Hugo F Relative inefficiency of terminal complement activation J Immunol 141 1988 3117 3122
28. Guidoin RG Awad JA Laparche Y Morin PJ Haggis GH Naure of deposits in a tubular membrane oxygenator after prolonged extracorporeal circulation J T horac C ardiovasc S urg 69 1975 479 491
29. Chang TMS Platelet-surface interaction: effect of albumin coating or heparin complexing on thrombogenic surfaces Can J Physiol Pharmacol 52 1974 275 285
30. Bindslev L Guoda I Inacio J Extracorporeal elimination of carbon dioxide using a surface-heparinized venovenous bypass system Trans Am Soc Artif Intern Organs 32 1986 530 533
31. Rent R Ertel N Eisenstein R Gewurz H Complement activation by interaction of polyanions and polycations. 1. Heparin-protamine induced consumption of complement J Immunol 114 1975 120 124